
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
MAML2
Introduction
Mastermind-like protein 2 is a protein that in humans is encoded by the MAML2 gene.[1][2][3]
See also
See also
Details on the activity of the N-terminal domain of Mastermind-like protein 2 may be found under MamL-1.
References
References
- ↑ Wu L, Sun T, Kobayashi K, Gao P, Griffin JD (Oct 2002). “Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors”. Mol Cell Biol. 22 (21): 7688–700. doi:10.1128/MCB.22.21.7688-7700.2002. PMC 135662. PMID 12370315.
- ↑ Lin SE, Oyama T, Nagase T, Harigaya K, Kitagawa M (Dec 2002). “Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling”. J Biol Chem. 277 (52): 50612–20. doi:10.1074/jbc.M209529200. PMID 12386158.
- ↑ “Entrez Gene: MAML2 mastermind-like 2 (Drosophila)”.
Further reading
Further reading
- Nagase T, Nakayama M, Nakajima D, Kikuno R, Ohara O (2001). “Prediction of the coding sequences of unidentified human genes. XX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro”. DNA Res. 8 (2): 85–95. doi:10.1093/dnares/8.2.85. PMID 11347906.
- Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, O’Neil K, Stover K, El-Naggar A, Griffin JD, Kirsch IR, Kaye FJ (2003). “t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway”. Nat. Genet. 33 (2): 208–13. doi:10.1038/ng1083. PMID 12539049.
- Enlund F, Behboudi A, Andrén Y, Oberg C, Lendahl U, Mark J, Stenman G (2004). “Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin’s tumors”. Exp. Cell Res. 292 (1): 21–8. doi:10.1016/j.yexcr.2003.09.007. PMID 14720503.
- Behboudi A, Winnes M, Gorunova L, van den Oord JJ, Mertens F, Enlund F, Stenman G (2005). “Clear cell hidradenoma of the skin-a third tumor type with a t(11;19)–associated TORC1-MAML2 gene fusion”. Genes Chromosomes Cancer. 43 (2): 202–5. doi:10.1002/gcc.20168. PMID 15729701.
- Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, Griffin JD (2005). “Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation”. EMBO J. 24 (13): 2391–402. doi:10.1038/sj.emboj.7600719. PMC 1173159. PMID 15961999.
- Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M, Shimozato K, Eimoto T, Nakamura S, Nagai N, Hasegawa Y, Inagaki H (2007). “MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma”. Clin. Cancer Res. 12 (13): 3902–7. doi:10.1158/1078-0432.CCR-05-2376. PMID 16818685.
- Winnes M, Mölne L, Suurküla M, Andrén Y, Persson F, Enlund F, Stenman G (2007). “Frequent fusion of the CRTC1 and MAML2 genes in clear cell variants of cutaneous hidradenomas”. Genes Chromosomes Cancer. 46 (6): 559–63. doi:10.1002/gcc.20440. PMID 17334997.
- Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK (2007). “CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin’s tumors: implications for histogenesis and biologic behavior”. Genes Chromosomes Cancer. 46 (7): 708–15. doi:10.1002/gcc.20458. PMID 17437281.
- Nemoto N, Suzukawa K, Shimizu S, Shinagawa A, Takei N, Taki T, Hayashi Y, Kojima H, Kawakami Y, Nagasawa T (2007). “Identification of a novel fusion gene MLL-MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23)”. Genes Chromosomes Cancer. 46 (9): 813–9. doi:10.1002/gcc.20467. PMID 17551948.
